Business Context and Reporting Period
Company: LeMaitre Vascular, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: December 20, 2007
Event: Announcement of the acquisition of Biomateriali S.r.l., an Italian limited liability company, from Diaco S.p.A. and Invesco S.p.A.
Key Financial Metrics and Transaction Details
This filing details a specific acquisition transaction rather than periodic financial results. Key financial terms include:
- Base Purchase Price: Euro 1,800,000 in cash.
- Price Adjustment: Subject to adjustment based on changes in Biomateriali's tangible net worth between December 31, 2006, and December 20, 2007 (final determination by May 18, 2008).
- Assumed Liabilities: Euro 795,000 in intercompany liabilities owed to sellers and affiliates.
- Contingent Consideration: Up to Euro 1,500,000 payable upon termination of certain distribution arrangements (deadline: January 15, 2012).
- Exchange Rate: 1 Euro = 1.4398 U.S. Dollars (as of December 20, 2007).
Payment Schedule:
- Base Price: Euro 1,300,000 paid at closing; balance due March 20, 2009.
- Assumed Liabilities: Euro 355,000 (March 31, 2008), Euro 200,000 (January 30, 2009), and Euro 240,000 (March 31, 2009).
Note: The filing text does not provide clear values for the Company's overall revenue, profit, cash flow, margins, or total debt levels outside of this specific transaction.
Material Changes
The primary material change is the expansion of the Company's operations through the acquisition of all outstanding equity interests in Biomateriali S.r.l. This represents a new strategic asset and associated cash outflows and liabilities not present in the prior comparable period.
Outlook, Risks, and Contingencies
- Contingent Payments: The Company faces potential future cash outflows of up to Euro 1,500,000 dependent on the termination of specific distribution arrangements.
- Price Adjustment Risk: The final purchase price is not fixed and depends on the calculation of tangible net worth changes, to be finalized by May 18, 2008.
- Covenants: The agreement includes a five-year non-competition covenant from the sellers and provisions for transitional assistance.
- Indemnification: Sellers have agreed to indemnify the Company for losses arising from breaches or misrepresentations under the Agreement.
Investor Verification Checklist
- Verify the final calculation of the purchase price adjustment based on Biomateriali's tangible net worth (due May 18, 2008).
- Monitor the status of distribution arrangements to assess the likelihood of the Euro 1,500,000 contingent payment.
- Review the attached press release (Exhibit 99.1) for strategic rationale and integration plans.
- Confirm the impact of the Euro 795,000 assumed liabilities on the Company's liquidity and cash flow projections.